Phase 1 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 6 and 25 years old
- You have recently been diagnosed with Hodgkin Lymphoma or Non-Hodgkin Lymphoma (a new diagnosis)
- You are able to swallow medications by mouth, or receive them through a feeding tube placed through the nose
- You (or your parent/guardian if you are a child) are able to give written consent to take part
Who may not be able to join:
- You are allergic to omeprazole (a common heartburn medicine) or dextromethorphan (a common cough medicine used in the study)
- You have severe organ problems affecting the liver, kidneys, or digestive system (confirm with trial site)
- You have had cancer treatment before — this trial is only for people who have not yet been treated for cancer
- You are very unwell and need intensive care treatment
- Your cancer treatment needs to start urgently at a time when study staff are not available to explain the trial and get your consent beforehand
- You (or your parent/guardian) are unable to provide written consent to take part
⚠️ Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Rachel Conyers, MBBS (Hons), Murdoch Childrens Research Institute
Phone: +61393455522
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Proportion of patients who consent to study and complete baseline and at least two longitudinal timepoints with successful measurement of probe drug MR (Metabolic ratio)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.